GICS Sector : Healthcare
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.It is also developing AMX0035 for other neurodegenerative diseases.
Amylyx Pharmaceuticals reported a cash and marketable securities balance of $317 million at the end of the fourth quarter, down from $344 million in the third quarter. The company's financial performance was characterized by a significant investment in research and development, with a focus on advancing its pipeline, particularly Avexatide, a GLP-1 receptor antagonist in post-bariatric hypoglycemia (PBH). The actual EPS came out at '-0.3', slightly better than estimates at '-0.31'.
Publication Date: Mar -08
The company made meaningful progress in its pipeline, initiating the pivotal Phase III LUCIDITY trial of Avexatide, which is evaluating the drug's efficacy in reducing hypoglycemic events in individuals with PBH following Roux-en-Y gastric bypass surgery. As Justin B. Klee noted, "We believe that we are recruiting the right participants for the LUCIDITY study... The unmet need in PBH is a large orphan condition, and there are many people who are struggling with PBH, and there are no treatments approved for PBH right now."
Amylyx is working on the NDA to be prepared for a strong submission following the top-line results from the LUCIDITY trial, expected in Q3 2026. The company is also expanding its commercial and medical team's efforts in anticipation of a potential launch in 2027. Analysts estimate next year's revenue growth at 41426.7%, indicating significant potential for the company.
To understand what's priced into Amylyx's stock, we can look at various valuation metrics. The company's P/E Ratio is -9.05, P/B Ratio is 4.29, and EV/EBITDA is -6.46. These metrics suggest that the market is pricing in significant growth potential, but also reflects the high-risk nature of the biotech industry. The current valuation multiples indicate that the market expects a substantial increase in earnings and revenue in the future.
Amylyx is positioned for a transformative year in 2026, with the LUCIDITY trial top-line readout expected in Q3 2026, followed by potential FDA approval and commercial launch in 2027. The company's cash runway is anticipated to extend into 2028, providing sufficient capital to fund its operations through its expected milestones. With a strong pipeline and significant potential for growth, Amylyx is an attractive investment opportunity for those willing to take on the associated risks.
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Mar -15
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
Mar -14
Amylyx Pharmaceuticals Q4 Earnings Call Highlights
Mar -05
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
Mar -04
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout
Mar -04
Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
Mar -03
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Mar -03
Financial Survey: Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Theravance Biopharma (NASDAQ:TBPH)
Feb -10
Relyvrio's 10.27% growth driven by increasing ALS patient adoption, expanded insurance coverage, and strong marketing efforts. Amylyx's strategic partnerships and investments in clinical trials also contribute to growth. Additionally, the drug's unique mechanism of action and favorable safety profile support its rising demand.
AMX0035 is an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is being explored for its potential to treat other neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
Amylyx Pharmaceuticals, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for ALS and other neurodegenerative diseases.
Patients and healthcare providers have limited bargaining power due to the lack of effective treatment options for ALS, giving Amylyx Pharmaceuticals, Inc. an upper hand in pricing and negotiations.
Amylyx Pharmaceuticals, Inc. relies on a few key suppliers for raw materials and manufacturing services, giving them some bargaining power, but the company's strong financial position and diversified supply chain mitigate this risk.
The biotechnology industry is highly competitive, and new entrants with innovative treatments for ALS and other neurodegenerative diseases could potentially disrupt Amylyx Pharmaceuticals, Inc.'s market share.
The biotechnology industry is highly competitive, with multiple companies vying for market share and patent protection for their treatments, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 0.97% |
| Debt Cost | 3.95% |
| Equity Weight | 99.03% |
| Equity Cost | 0.53% |
| WACC | 0.57% |
| Leverage | 0.98% |
Value: 6.4
Growth: 9.4
Quality: 9.0
Yield: 0.0
Momentum: 5.0
Volatility: 4.3
1-Year Total Return ->
Value: 7.3
Growth: 6.0
Quality: 8.6
Yield: 0.0
Momentum: 9.0
Volatility: 1.3
1-Year Total Return ->
Value: 7.8
Growth: 3.6
Quality: 4.4
Yield: 0.0
Momentum: 8.0
Volatility: 5.7
1-Year Total Return ->
Value: 3.2
Growth: 6.2
Quality: 9.4
Yield: 0.0
Momentum: 10.0
Volatility: 0.3
1-Year Total Return ->
Value: 8.7
Growth: 3.6
Quality: 6.8
Yield: 0.0
Momentum: 5.0
Volatility: 2.0
1-Year Total Return ->
Value: 8.0
Growth: 6.9
Quality: 3.5
Yield: 0.0
Momentum: 0.5
Volatility: 0.0
1-Year Total Return ->